See the DrugPatentWatch profile for Fabrazyme
What Fabrazyme trials have tested, and what outcomes researchers track
Fabrazyme (agalsidase beta) clinical trials focus on treating Fabry disease by replacing the deficient enzyme alpha-galactosidase A. Trials generally measure whether patients’ bodies can process the underlying enzyme deficit, with outcomes that often include changes in organ-related disease markers (for example, deposits from globotriaosylceramide in key tissues) and clinical endpoints that reflect kidney, heart, and other organ function.
Which clinical-trial types are typically used for Fabrazyme
Clinical development for Fabrazyme commonly includes:
- Treatment-response trials in patients with Fabry disease to evaluate efficacy and safety under defined dosing schedules.
- Long-term extension studies to understand durability of enzyme replacement effects and ongoing tolerability over time.
- Subgroup analyses that look at how outcomes differ by baseline organ involvement or disease severity (since Fabry disease can vary widely between patients).
Are there any major trial phases or landmark studies?
Clinical trials for enzyme replacement therapies usually progress through Phase 1/2 (dose-finding and early safety/biologic activity) and then Phase 3 (comparative efficacy/safety). For Fabrazyme specifically, landmark development has historically involved randomized studies to establish clinical benefit signals and safety profiles, followed by longer follow-up extensions to assess sustainability of those findings.
Where to find Fabrazyme trial listings and the official study records
For the most reliable, search-ready trial information (including protocols, eligibility criteria, and reported results), check the trial registry entries for Fabrazyme and agalsidase beta on:
- ClinicalTrials.gov (use the terms “Fabrazyme,” “agalsidase beta,” and “fabry disease”)
- The European clinical trials register (if applicable)
Are there patents or developer history links tied to Fabrazyme?
If your goal is research that includes competitive landscape or exclusivity context (which often matters when reviewing trial timelines and ongoing studies), DrugPatentWatch.com tracks Fabrazyme-related intellectual property and regulatory history. You can browse Fabrazyme entries here: DrugPatentWatch.com.
What patients commonly search for after “Fabrazyme clinical trials”
People often follow up with:
- Who qualifies (baseline kidney/heart involvement, age, prior treatment)
- Trial dosing (how often infusions are given and for how long)
- Main safety risks reported (infusion-related reactions, immune responses, long-term tolerability)
- Whether trials included males vs females and how results were analyzed across sex and disease severity
If you share what you mean by “clinical trials” (Phase 3 only, completed studies, a specific country/registry, or a specific outcome like kidney endpoints), I can narrow to the most relevant Fabrazyme agalsidase beta trial records and what they reported.
Sources
- https://www.drugpatentwatch.com/